Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,108 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial.
Masuda N, Toi M, Yamamoto N, Iwata H, Kuroi K, Bando H, Ohtani S, Takano T, Inoue K, Yanagita Y, Kasai H, Morita S, Sakurai T, Ohno S. Masuda N, et al. Among authors: kasai h. Breast Cancer. 2018 Jul;25(4):407-415. doi: 10.1007/s12282-018-0839-7. Epub 2018 Feb 14. Breast Cancer. 2018. PMID: 29445928 Free PMC article. Clinical Trial.
[Antiangiogenic and antitumor effect of BPHA, an orally-active matrix metalloproteinase inhibitor, in in vivo murine and human tumor model].
Maki H, Maekawa R, Yoshida H, Hojo K, Uchida N, Wada T, Tanaka H, Takeda Y, Matsumoto M, Yamada H, Nishitani Y, Shono K, Kasai H, Sato S, Okamoto H, Hayashi R, Tamura Y, Tsuzuki H, Watanabe F, Sugita K, Yoshioka T. Maki H, et al. Among authors: kasai h. Gan To Kagaku Ryoho. 1999 Oct;26(11):1599-606. Gan To Kagaku Ryoho. 1999. PMID: 10553417 Japanese.
Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor.
Maekawa R, Maki H, Yoshida H, Hojo K, Tanaka H, Wada T, Uchida N, Takeda Y, Kasai H, Okamoto H, Tsuzuki H, Kambayashi Y, Watanabe F, Kawada K, Toda K, Ohtani M, Sugita K, Yoshioka T. Maekawa R, et al. Among authors: kasai h. Cancer Res. 1999 Mar 15;59(6):1231-5. Cancer Res. 1999. PMID: 10096553
1,108 results